- Home
- ATYR vs SSBK Comparison
ATYR vs SSBK Comparison
Compare ATYR & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SSBK
- Stock Information
- Founded
- ATYR 2005
- SSBK 2007
- Country
- ATYR United States
- SSBK United States
- Employees
- ATYR N/A
- SSBK N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SSBK Commercial Banks
- Sector
- ATYR Health Care
- SSBK Finance
- Exchange
- ATYR Nasdaq
- SSBK Nasdaq
- Market Cap
- ATYR 290.6M
- SSBK N/A
- IPO Year
- ATYR 2015
- SSBK 2021
- Fundamental
- Price
- ATYR $3.34
- SSBK $35.53
- Analyst Decision
- ATYR Strong Buy
- SSBK Buy
- Analyst Count
- ATYR 6
- SSBK 1
- Target Price
- ATYR $18.60
- SSBK $36.00
- AVG Volume (30 Days)
- ATYR 1.1M
- SSBK 41.8K
- Earning Date
- ATYR 05-07-2025
- SSBK 04-21-2025
- Dividend Yield
- ATYR N/A
- SSBK 1.01%
- EPS Growth
- ATYR N/A
- SSBK 6.02
- EPS
- ATYR N/A
- SSBK 3.80
- Revenue
- ATYR N/A
- SSBK $99,026,000.00
- Revenue This Year
- ATYR $551.06
- SSBK $19.18
- Revenue Next Year
- ATYR $2,144.84
- SSBK $7.05
- P/E Ratio
- ATYR N/A
- SSBK $9.36
- Revenue Growth
- ATYR N/A
- SSBK 18.43
- 52 Week Low
- ATYR $1.42
- SSBK $24.86
- 52 Week High
- ATYR $4.66
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- ATYR 51.21
- SSBK 63.53
- Support Level
- ATYR $3.06
- SSBK $34.44
- Resistance Level
- ATYR $3.67
- SSBK $35.37
- Average True Range (ATR)
- ATYR 0.25
- SSBK 0.74
- MACD
- ATYR 0.01
- SSBK 0.28
- Stochastic Oscillator
- ATYR 46.77
- SSBK 93.37
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.